Numelvi is a drug owned by INTERVET, INC. It is protected by 4 US drug patents filed from 2033 to 2043. All patents are active. Details of Numelvi’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US10875847 | 13 Dec, 2037 | Active |
| US9394282 | 03 Jan, 2033 | Active |
Exclusivity Information
Numelvi holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Numelvi's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Feb 25, 2031 |
About Numelvi
Numelvi is a drug
owned by INTERVET, INC.
Numelvi uses
Atinvicitinib as the active
ingredient.
Active Ingredient:
Numelvi uses
Atinvicitinib as the active ingredient.
Check out other Drugs and Companies using
Atinvicitinib ingredient.